Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Jul:155 Suppl 1:S11-5.
doi: 10.1007/pl00014222.

Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria

P Burgard  1 , A Rupp, D S Konecki, F K Trefz, H Schmidt, U Lichter-Konecki
Affiliations

Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria

P Burgard et al. Eur J Pediatr. 1996 Jul.

Abstract

The interdependence of the predicted in vitro residual enzyme activity (PRA), as deduced from the complete genotypes of 64 hyperphenylalaninaemic patients, and parameters for diagnosis of hyperphenylalaninaemic disorders, the fluctuation of the phyenlylalanine (Phe) values during treatment, long-term dietary control during treatment, and a parameter for the outcome of therapy (IQ) was investigated by correlation analysis. A highly significant correlation was found between the PRA and diagnostic parameters, as well as the fluctuation of the Phe values during treatment. Significant correlations were also observed between the parameter describing the fluctuation of the Phe values and the IQ, as well as between the quality of dietary control and IQ. The PRA is a valuable tool for the differential diagnosis of hyperphenylalaninaemic disorders and for the prediction of one aspect of the course of the disease which is related to the intellectual outcome of therapy. The quality of dietary control was independent of the genotype, indicating that the outcome of therapy can be successfully manipulated in spite of the genetic make-up.

PubMed Disclaimer

References

    1. N Engl J Med. 1991 May 2;324(18):1232-8 - PubMed
    1. Hum Mutat. 1992;1(1):13-23 - PubMed
    1. Eur J Pediatr. 1993 Dec;152(12):1048-9 - PubMed
    1. Somat Cell Mol Genet. 1991 May;17(3):303-9 - PubMed
    1. Genomics. 1991 Oct;11(2):242-6 - PubMed

Publication types

Substances

LinkOut - more resources